U.S., Nov. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07939230) titled 'Evaluation of FLT3L Armoured CAR T-cells in HER2 Expressing Malignant Diseases in Adults' on Sept. 02.

Brief Summary: The goal of this clinical trial is to learn if a novel CAR-T cell therapy, called autologous PMCC-COE-HER2FLT3L CAR-T cells, is safe and effective at treating solid tumours that express high levels of the marker HER-2. Patients who have solid tumours that express the marker HER-2, and who have previously progressed or where unsuitable for current HER-2 targeted medications, will be recruited to the study. The PMCC-COE-HER2FLT3L CAR T-cells will be produced using LV and administered to patients after lymphodepleting c...